BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 V299L
|
CML
|
BCR-ABL1 V299L
|
CML
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 V299L
|
CML
|
BCR-ABL1 V299L
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 V299L
|
CML
|
BCR-ABL1 V299L
|
CML
|
nilotinib Sensitive: D – Preclinical
|
nilotinib Sensitive: D – Preclinical
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
crizotinib Sensitive: D – Preclinical
|
crizotinib Sensitive: D – Preclinical
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
GSK1363089 Sensitive: D – Preclinical
|
GSK1363089 Sensitive: D – Preclinical
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
cabozantinib capsule Sensitive: D – Preclinical
|
cabozantinib capsule Sensitive: D – Preclinical
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
vandetanib Sensitive: D – Preclinical
|
vandetanib Sensitive: D – Preclinical
|
BCR-ABL1 V299L
|
CML
|
BCR-ABL1 V299L
|
CML
|
imatinib Sensitive: D – Preclinical
|
imatinib Sensitive: D – Preclinical
|